Join
Live feed
·
PRReleasevia Quantisnow
Rein Therapeutics Inc. logo

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
RNTX· Rein Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RNTX (Rein Therapeutics Inc.) and more on Quantisnow.